Novartis AG

Overview Alexion is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris® (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. We are also evaluating other potential...

Related "Novartis AG" Articles

OverviewAlexion is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris®...

U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation. If approved by the...

CHICAGO (Reuters) - At an ill-fated press conference in 1984, U.S. Health and Human Services Secretary Margaret Heckler boldly predicted an effective AIDS vaccine would be available within just two years. But a string of failed attempts - punctuated by...

NEW YORK (Reuters Health) - Results from a large U.S. study suggest women who regularly exercise vigorously, including runners and aerobics buffs, may be less likely to get psoriasis than less-active women. Researchers have known that people who are...

SAN ANTONIO (AP) — Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse. In a large...

NEW YORK (Reuters Health) - One class of drugs used to prevent wheezing and shortness of breath in people with asthma may increase kids' risk of being hospitalized for an asthma attack, according to a new analysis from the U.S. Food and Drug...

STOCKHOLM (Reuters) - Roche's bone strengthening drug Boniva is as good for pain relief as single dose radiotherapy in patients whose prostate cancer has spread to their bones, according to data from a late-stage trial released on Sunday.
Trial...

ZURICH (Reuters) - Doctors and investors at a cancer conference starting on Friday will be keen to find out more on the effectiveness of two promising new breast cancer drugs from Swiss drugmakers Roche and Novartis.
Roche's T-DM1 and Novartis's Afinitor...

NEW YORK (Reuters Health) - A new study adds to evidence that skin patches offer a safer alternative to pills for women who want to treat their menopausal symptoms with hormones.
The study, of 54,000 women who used hormone replacement therapy (HRT),...

We've long been told to keep an eye on our moles lest they progress to melanoma, a form of skin cancer that's treatable if caught early, deadly if not. But not all moles are equal -- some are risky; others can be safely left alone. The biological roots of...